+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNAi Therapeutics Market - Global Forecast 2026-2032- Product Image
RNAi Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

RNAi Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6124468
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The RNAi Therapeutics Market is projected to reach USD 6.36 Billion in 2026. It is expected to continue growing at a CAGR of 15.53%, reaching USD 15.23 Billion by 2032.

RNAi Therapeutics: Executive Summary and Strategic Context

RNA interference (RNAi) therapeutics use short interfering RNA or related molecules to selectively reduce expression of disease-associated genes. The field has progressed from a novel gene-silencing concept to an established therapeutic modality, supported by advances in sequence design, chemical stabilization, conjugation, and delivery systems. Clinical development spans rare diseases, cardiometabolic conditions, infectious diseases, liver disorders, and oncology, although delivery beyond well-characterized tissues remains a central scientific challenge.

Delivery, Durability, and Biomarker Translation Are Reshaping RNAi Development

The landscape is shifting toward more precise delivery vehicles, longer dosing intervals, and biomarker-led development. Ligand conjugates and lipid-based nanoparticles have improved uptake in selected tissues, while advances in formulation and chemical modification aim to reduce off-target activity, immune activation, and repeat-dosing burdens. Regulatory experience with approved RNAi medicines is also strengthening expectations for pharmacodynamic evidence, clinically meaningful endpoints, manufacturing control, and long-term safety monitoring.

Artificial Intelligence Accelerates RNAi Design, but Experimental Validation Remains Essential

Artificial intelligence can support target identification, sequence optimization, secondary-structure analysis, delivery-vehicle selection, toxicity screening, and interpretation of multi-omics data. These tools may shorten iteration cycles by prioritizing candidates with stronger predicted specificity and tissue compatibility. However, model outputs remain dependent on data quality and biological assumptions; laboratory testing, animal studies, clinical biomarkers, and regulatory review remain necessary to confirm efficacy, durability, immunogenicity, and safety.

Regional Dynamics Reflect Research Strength, Manufacturing Capacity, and Regulatory Readiness

North America combines substantial translational research, venture activity, clinical infrastructure, and regulatory experience. Europe benefits from strong academic networks and coordinated regulatory and health-technology assessment frameworks, while Asia-Pacific is supported by expanding biopharmaceutical capabilities, clinical research capacity, and growing investment in advanced modalities. Latin America is developing through specialist centers and partnership-led access models. The Middle East is building biotechnology and precision-medicine capabilities, and Africa presents important opportunities for locally relevant research, diagnostics, and delivery partnerships alongside persistent infrastructure and access constraints.

International Groupings Influence Collaboration, Standards, and Access Pathways

ASEAN economies are relevant to regional manufacturing, clinical-trial networks, and healthcare-access partnerships. BRICS members provide a broad base of scientific, manufacturing, and patient-population capabilities, with substantial variation in regulatory maturity. The European Union supports cross-border research and regulatory coordination, while the G7 contributes advanced biomedical research, capital, and standards development. GCC countries are investing in healthcare modernization and biotechnology infrastructure. NATO members offer extensive research and health-security networks, though defense alignment does not eliminate differences in national reimbursement, trial, and procurement systems.

Country-Level Priorities Range from Discovery Leadership to Manufacturing and Access

The United States remains a major center for RNAi discovery, clinical development, and regulatory precedent. Canada contributes academic research and biotechnology capacity. The United Kingdom, France, Germany, Italy, and Spain combine strong biomedical institutions with European regulatory and reimbursement considerations. China is expanding research, clinical, and manufacturing capabilities, while Japan and South Korea bring advanced pharmaceutical, delivery, and translational expertise. India is strengthening biopharmaceutical development and cost-efficient manufacturing. Australia supports clinical research and life-sciences collaboration. Brazil and Mexico are important Latin American markets for research partnerships and access planning. Russia retains scientific and manufacturing capabilities, although collaboration and supply-chain considerations are affected by geopolitical and regulatory conditions.

Industry Leaders Should Prioritize Validated Delivery, Evidence Quality, and Partnership Design

Leaders should focus portfolios on targets with compelling human biology, measurable pharmacodynamic biomarkers, and a credible path to tissue delivery. Development plans should integrate sequence specificity, immunogenicity, repeat-dose safety, manufacturability, and patient adherence from the outset. Strategic partnerships can combine discovery, delivery technology, clinical networks, diagnostics, and local regulatory expertise. Organizations should also establish responsible AI governance, protect sequence and patient data, design region-specific access strategies, and engage regulators early on long-term follow-up and comparability requirements.

Research Methodology: Evidence Triangulation Across Science, Regulation, and Healthcare Systems

This executive summary is based on structured analysis of the RNAi therapeutics field, including peer-reviewed scientific literature, clinical-trial registries, regulatory communications, approved-product information, company and academic disclosures, manufacturing and delivery research, and publicly available healthcare-policy sources. Findings are synthesized across therapeutic biology, delivery technologies, clinical development, regulatory practice, regional capability, and access conditions. Claims are limited to documented qualitative insights; no market estimates, market shares, forecasts, or company-specific rankings are included.

RNAi Therapeutics Are Advancing Through Precision, Durability, and Evidence Discipline

RNAi therapeutics have established a durable role in modern drug development, with their strongest progress linked to selective gene silencing, improved delivery, and clinically useful dosing intervals. Future advancement will depend on extending reliable delivery into additional tissues, demonstrating durable patient benefit, and managing safety and manufacturing complexity at scale. Organizations that combine rigorous biology with data-driven design, robust clinical evidence, cross-border collaboration, and practical access planning will be best positioned to translate RNAi potential into broader therapeutic impact.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. RNAi Therapeutics Market, by Delivery Technology
7.1. Introduction
7.2. Exosomes
7.3. GalNAc Conjugates
7.4. Lipid Nanoparticles
7.5. Polymeric Nanoparticles
7.6. Viral Vectors
8. RNAi Therapeutics Market, by Therapeutic Molecule Type
8.1. Introduction
8.2. Microrna
8.3. Short Hairpin Rna
8.4. Small Interfering Rna
9. RNAi Therapeutics Market, by Development Stage
9.1. Introduction
9.2. Commercial
9.3. Phase I
9.4. Phase Ii
9.5. Phase Iii
9.6. Preclinical
10. RNAi Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Intranasal
10.3. Intravenous
10.4. Intravitreal
10.5. Subcutaneous
11. RNAi Therapeutics Market, by Formulation Type
11.1. Introduction
11.2. Liquid Formulation
11.3. Lyophilized Formulation
12. RNAi Therapeutics Market, by Indication
12.1. Introduction
12.2. Cardiovascular Disorders
12.3. Infectious Diseases
12.4. Metabolic Disorders
12.5. Oncology
12.5.1. Hematological Malignancies
12.5.1.1. Leukemia
12.5.1.2. Lymphoma
12.5.1.3. Myeloma
12.5.2. Solid Tumors
12.5.2.1. Breast Cancer
12.5.2.2. Liver Cancer
12.5.2.3. Lung Cancer
12.6. Rare Diseases
13. RNAi Therapeutics Market, by End User
13.1. Introduction
13.2. Academic Institutions
13.3. Hospitals
13.4. Research Laboratories
13.5. Specialty Clinics
14. RNAi Therapeutics Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. RNAi Therapeutics Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. RNAi Therapeutics Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Alnylam Pharmaceuticals, Inc.
18.2. Arbutus Biopharma Corporation
18.3. Arbutus Biopharma Corporation
18.4. Arrowhead Pharmaceuticals, Inc.
18.5. Benitec Biopharma Limited
18.6. Dynacure SAS
18.7. Novartis AG
18.8. OliX Pharmaceuticals, Inc.
18.9. Ona Therapeutics SL
18.10. Phio Pharmaceuticals Corp.
18.11. Quark Pharmaceuticals, Inc.
18.12. Roche Holding AG
18.13. Silence Therapeutics plc
18.14. Simaomics, Inc.
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global RNAi Therapeutics Market, Years Considered for the Study
FIGURE 2. Global RNAi Therapeutics Market, Research Design
FIGURE 3. Global RNAi Therapeutics Market, Research Framework
FIGURE 4. Global RNAi Therapeutics Market, Data Triangulation
FIGURE 5. Global RNAi Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global RNAi Therapeutics Market Size, by Delivery Technology, 2025 vs 2032 (%)
FIGURE 7. Global RNAi Therapeutics Market Size, by Delivery Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2025 vs 2032 (%)
FIGURE 9. Global RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global RNAi Therapeutics Market Size, by Development Stage, 2025 vs 2032 (%)
FIGURE 11. Global RNAi Therapeutics Market Size, by Development Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global RNAi Therapeutics Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 13. Global RNAi Therapeutics Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global RNAi Therapeutics Market Size, by Formulation Type, 2025 vs 2032 (%)
FIGURE 15. Global RNAi Therapeutics Market Size, by Formulation Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global RNAi Therapeutics Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 17. Global RNAi Therapeutics Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global RNAi Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 19. Global RNAi Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global RNAi Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global RNAi Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global RNAi Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global RNAi Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global RNAi Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global RNAi Therapeutics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global RNAi Therapeutics Market Segmentation & Coverage
TABLE 2. Global RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 4. Global Exosomes Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Exosomes Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Exosomes Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global GalNAc Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global GalNAc Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global GalNAc Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Polymeric Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Polymeric Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Polymeric Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Viral Vectors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Viral Vectors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Viral Vectors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 20. Global Microrna Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Microrna Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Microrna Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Short Hairpin Rna Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Short Hairpin Rna Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Short Hairpin Rna Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Small Interfering Rna Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Small Interfering Rna Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Small Interfering Rna Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 30. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Phase Ii Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Phase Ii Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Phase Ii Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Phase Iii Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Phase Iii Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Phase Iii Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 46. Global Intranasal Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Intranasal Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Intranasal Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Intravitreal Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Intravitreal Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Intravitreal Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 59. Global Liquid Formulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Liquid Formulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Liquid Formulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Lyophilized Formulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Lyophilized Formulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Lyophilized Formulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 66. Global Cardiovascular Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Cardiovascular Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Cardiovascular Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Myeloma Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Myeloma Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Myeloma Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Liver Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Liver Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Liver Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Rare Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Rare Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Rare Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 106. Global Academic Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Academic Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Academic Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Research Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Research Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Research Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Asia-Pacific RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 128. Asia-Pacific RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. North America RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. North America RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 132. North America RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 133. North America RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 134. North America RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. North America RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 136. North America RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. North America RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 138. North America RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 139. North America RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 140. North America RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. Latin America RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Latin America RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 143. Latin America RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 144. Latin America RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 145. Latin America RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. Latin America RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 147. Latin America RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 148. Latin America RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 149. Latin America RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 150. Latin America RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 151. Latin America RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. Europe RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Europe RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 154. Europe RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 155. Europe RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 156. Europe RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 157. Europe RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 158. Europe RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. Europe RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 160. Europe RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 161. Europe RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 162. Europe RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. Middle East RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Middle East RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 165. Middle East RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 166. Middle East RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 167. Middle East RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 168. Middle East RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 169. Middle East RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. Middle East RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 171. Middle East RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 172. Middle East RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 173. Middle East RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. Africa RNAi Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 175. Africa RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 176. Africa RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 177. Africa RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 178. Africa RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 179. Africa RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 180. Africa RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 181. Africa RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 182. Africa RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 183. Africa RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 184. Africa RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Global RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. ASEAN RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. ASEAN RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 188. ASEAN RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 189. ASEAN RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 190. ASEAN RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. ASEAN RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 192. ASEAN RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 193. ASEAN RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 194. ASEAN RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 195. ASEAN RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 196. ASEAN RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. GCC RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. GCC RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 199. GCC RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 200. GCC RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 201. GCC RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 202. GCC RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 203. GCC RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 204. GCC RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 205. GCC RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 206. GCC RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 207. GCC RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. European Union RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 209. European Union RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 210. European Union RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 211. European Union RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 212. European Union RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 213. European Union RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 214. European Union RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. European Union RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 216. European Union RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 217. European Union RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 218. European Union RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. BRICS RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 220. BRICS RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 221. BRICS RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 222. BRICS RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 223. BRICS RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 224. BRICS RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 225. BRICS RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. BRICS RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 227. BRICS RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 228. BRICS RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 229. BRICS RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. G7 RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. G7 RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 232. G7 RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 233. G7 RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 234. G7 RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 235. G7 RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 236. G7 RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 237. G7 RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 238. G7 RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 239. G7 RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 240. G7 RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. NATO RNAi Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 242. NATO RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 243. NATO RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 244. NATO RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 245. NATO RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 246. NATO RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 247. NATO RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 248. NATO RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 249. NATO RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 250. NATO RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 251. NATO RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. Global RNAi Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 253. United States RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 254. United States RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 255. United States RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 256. United States RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 257. United States RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 258. United States RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 259. United States RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 260. United States RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 261. United States RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 262. United States RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 263. United States RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. Canada RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 265. Canada RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 266. Canada RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 267. Canada RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 268. Canada RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 269. Canada RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 270. Canada RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 271. Canada RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 272. Canada RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 273. Canada RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 274. Canada RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Mexico RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 276. Mexico RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 277. Mexico RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 278. Mexico RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 279. Mexico RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. Mexico RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 281. Mexico RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 282. Mexico RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 283. Mexico RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 284. Mexico RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 285. Mexico RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. Brazil RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 287. Brazil RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 288. Brazil RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 289. Brazil RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 290. Brazil RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 291. Brazil RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 292. Brazil RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 293. Brazil RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 294. Brazil RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 295. Brazil RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 296. Brazil RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 297. United Kingdom RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 298. United Kingdom RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 299. United Kingdom RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 300. United Kingdom RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 301. United Kingdom RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 302. United Kingdom RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 303. United Kingdom RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 304. United Kingdom RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 305. United Kingdom RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 306. United Kingdom RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 307. United Kingdom RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 308. Germany RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 309. Germany RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 310. Germany RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 311. Germany RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 312. Germany RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 313. Germany RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 314. Germany RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 315. Germany RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 316. Germany RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 317. Germany RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 318. Germany RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 319. France RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 320. France RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 321. France RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 322. France RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 323. France RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 324. France RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 325. France RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 326. France RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 327. France RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 328. France RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 329. France RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 330. Russia RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 331. Russia RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 332. Russia RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 333. Russia RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 334. Russia RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 335. Russia RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 336. Russia RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 337. Russia RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 338. Russia RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 339. Russia RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 340. Russia RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 341. Italy RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 342. Italy RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 343. Italy RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 344. Italy RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 345. Italy RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 346. Italy RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 347. Italy RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 348. Italy RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 349. Italy RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 350. Italy RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 351. Italy RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 352. Spain RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 353. Spain RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 354. Spain RNAi Therapeutics Market Size, by Therapeutic Molecule Type, 2017-2032 (USD Million)
TABLE 355. Spain RNAi Therapeutics Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 356. Spain RNAi Therapeutics Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 357. Spain RNAi Therapeutics Market Size, by Formulation Type, 2017-2032 (USD Million)
TABLE 358. Spain RNAi Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 359. Spain RNAi Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 360. Spain RNAi Therapeutics Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 361. Spain RNAi Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 362. Spain RNAi Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 363. China RNAi Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 364. China RNAi Therapeutics Market Size, by Delivery Technology, 2017-2032 (USD Million)
TA

Companies Mentioned

  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • Benitec Biopharma Limited
  • Dynacure SAS
  • Novartis AG
  • OliX Pharmaceuticals, Inc.
  • Ona Therapeutics SL
  • Phio Pharmaceuticals Corp.
  • Quark Pharmaceuticals, Inc.
  • Roche Holding AG
  • Silence Therapeutics plc
  • Simaomics, Inc.

Related Topics

Related Reports

Antisense & RNAi Therapeutics Market - Global Forecast 2026-2032 - Product Image

Antisense & RNAi Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Antisense & RNAi Therapeutics Market Size, Share, Trends and Forecast by Technology, Route of Administration, Application, and Region, 2026-2034 - Product Image

Antisense & RNAi Therapeutics Market Size, Share, Trends and Forecast by Technology, Route of Administration, Application, and Region, 2026-2034

  • Report
  • 145 Pages
  • Global
From
RNAi Therapeutics Market (3rd Edition) by Type of RNAi Molecule, Therapeutic Area, Route of Administration, Key Geographical Regions, Sales Forecast and Leading Industry Players - Trends and Forecast Till 2035 - Product Image

RNAi Therapeutics Market (3rd Edition) by Type of RNAi Molecule, Therapeutic Area, Route of Administration, Key Geographical Regions, Sales Forecast and Leading Industry Players - Trends and Forecast Till 2035

  • Report
  • 423 Pages
  • Global
From
Antisense and RNAi Therapeutics - Global Strategic Business Report - Product Image

Antisense and RNAi Therapeutics - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
RNAi Technology - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

RNAi Technology - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.